{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-005445","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.144075+00:00","generated_at":"2026-05-31T10:15:12.566529+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aethlon Medical receives second ethics approval for Hemopurifier cancer trial in Australia","bullets":["Bellberry Human Research Ethics Committee granted full ethics approval to Pindara Private Hospital for Hemopurifier trial in solid tumors not responding to anti-PD-1 antibodies.","This is the second ethics committee approval; the first came from Royal Adelaide Hospital in June 2024.","The trial will be conducted by Dr. Marco Matos at Pindara Private Hospital in Queensland, Australia.","Next steps include Research Governance Office approval, then Site Initiation Visits before patient enrollment can begin.","Primary endpoint is safety; the trial plans to enroll 9–18 patients and will explore extracellular vesicle reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-005445","json":"https://secwatch.observer/filing/0001683168-24-005445.json","markdown":"https://secwatch.observer/filing/0001683168-24-005445.md","text":"https://secwatch.observer/filing/0001683168-24-005445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316824005445/0001683168-24-005445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316824005445/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:15:12.566529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}